Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT), Ligand Pharma (NASDAQ: LGND) and Seagen (NASDAQ: SGEN)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORTResearch Report), Ligand Pharma (LGNDResearch Report) and Seagen (SGENResearch Report) with bullish sentiments.

Corcept Therapeutics (CORT)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics today and set a price target of $29.00. The company’s shares closed last Thursday at $20.29.

According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 28.4% and a 45.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Janux Therapeutics Inc, and Corvus Pharmaceuticals.

Corcept Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $29.00.

See today’s analyst top recommended stocks >>

Ligand Pharma (LGND)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ligand Pharma, with a price target of $310.00. The company’s shares closed last Thursday at $118.96.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 28.2% and a 47.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ligand Pharma with a $250.00 average price target.

Seagen (SGEN)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Seagen today and set a price target of $200.00. The company’s shares closed last Thursday at $146.95.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 16.2% and a 46.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Global Blood Therapeutics, and Phasebio Pharmaceuticals.

Currently, the analyst consensus on Seagen is a Moderate Buy with an average price target of $175.20, implying a 19.9% upside from current levels. In a report issued on July 21, Oppenheimer also maintained a Buy rating on the stock with a $208.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.